Read new research studies published in the Journal and presented at the ESMO Congress.

Evidence suggests that combining metformin with standard of care could increase survival and offer other benefits to patients with high-volume disease.

The European Society for Medical Oncology (ESMO) 2024 meeting was a well-attended affair at the sprawling Fira Gran Via centre in Barcelona. Amongst the excited hustle and bustle of new data and ...

Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future ...

Panelist discusses how the second interim overall survival data from MARIPOSA-2, presented at the European Society for ...

The latest edition of EMJ Oncology is out now, featuring coverage from the 2024 European Society for Medical Oncology ...

The largest ever clinical trial of T cell therapy (a type of cell-based immunotherapy) for solid tumours has been completed. Led by a Singapore clinician-investigator, the global, international, ...

Driven by the early approval of its updated COVID-19 vaccine, BioNTech far exceeded analysts’ expectations in the third ...

This Industry Satellite Symposium was presented at the European Society for Medical Oncology (ESMO) Congress 2024, held in ...

ECHO, a proprietary diagnostic for detection of ecDNA amplified oncogenes In September, analytical validation data was presented at the European Society for Medical Oncology (ESMO) Congress for the ...

Additionally, positive findings from trials like ADRIATIC (NCT03703297) and IMforte (NCT05091567) are further shaping ...

Data from the squamous cell carcinoma of the head and neck cohort of this study were presented at the 2024 European Society for Medical Oncology congress in September that demonstrated the cohort met ...